In CML, individuals without heart failure no longer exhibited an increased mortality associated with SGLT2 inhibitor use (HR 1.49, 95% CI 0.35–6.32, p = 0.588) (data not shown). This evidence concerns the gene SLC5A2 and chronic myelogenous leukemia, BCR-ABL1 positive.